© 2020 MJH Life Sciences and Contemporary OB/GYN. All rights reserved.
Breast Health
Improving risk outcomes: Invasive breast cancer after DCIS
July 08, 2020
Women with ductal carcinoma in situ (DCIS) may experience higher risk of developing invasive breast cancer (IBC) and of death from breast cancer than the general population, according to new research.
Aromatase inhibitors for climacteric symptoms in women with breast cancer
July 08, 2020
New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.
Link between hormone replacement therapy and mammographic density
July 06, 2020
The review concluded that the highest increase in MD is among current users of HRT, particularly those taking continuous estrogen plus progestin (CEP).
Breast density laws and patient knowledge
June 23, 2020
Currently, 38 states and the District of Columbia have enacted dense breast notification (DBN) laws mandating that mammogram results include language informing women of risks related to dense breasts.
PARP inhibitors: Choosing what to use in epithelial ovarian cancer
June 23, 2020
Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.
Survival benefit in advanced or metastatic breast cancer with visceral metastases
June 12, 2020
Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.
PD-L1 CNA as a biomarker in metastatic breast cancer
June 10, 2020
Australian researchers believe that PD-L1 may have potential as an indicator of potential response to chemotherapy in women with metastatic breast cancer. That was based on results of a randomized trial, presented at the European Society for Medical Oncology in Lugano, Switzerland.
Text messages do not increase AI adherence for early-stage breast cancer
June 04, 2020
Long-term adherence improvements, it appears, require personalized and sustained behavioral interventions. TMs for AI should also be personalized for individual success.
Breast implants: FDA issues new labeling guidance
October 29, 2019
The agency issued the guidance in response to concerns that some women are not receiving and/or understanding information about the risks and benefits of the devices.
8 examples of how GBCA improves MRI
October 03, 2019
Gadolinium-based intravenous contrast agents (GBCA) provide additional information based on signal intensity changes after GBCA administration.